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Background. Somatic cytidine mutations in normal mammalian nuclear genes occur during antibody diversification in B
lymphocytes and generate an isoform of apolipoprotein B in intestinal cells by RNA editing. Here, I describe that succinate
dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal
peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia. Germ line mutations in the SDHB, SDHC or SDHD genes
cause hereditary paraganglioma (PGL) tumors which show constitutive activation of homeostatic mechanisms induced by
oxygen deprivation (hypoxia). Principal Findings. To determine the prevalence of a mutation identified in the SDHB mRNA,
180 samples are tested. An SDHB stop-codon mutation c.136C.T (R46X) is present in a significant fraction (average= 5.8%,
range = less than 1 to 30%, n = 52) of the mRNAs obtained from PBMCs. In contrast, the R46X mutation is present in the
genomic DNA of PBMCs at very low levels. Examination of the PBMC cell-type subsets identifies monocytes and natural killer
(NK) cells as primary sources of the mutant transcript, although lesser contributions also come from B and T lymphocytes.
Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational
mechanism targeting SDHB is operational in T-cell acute leukemia. Accordingly, substantial levels (more than 3%) of the
mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow
samples, but in none of 20 B-ALL samples. In addition, distinct heterozygous SDHB missense DNA mutations are identified in
Jurkat and TALL-104 cell lines which are derived from T-ALLs. Conclusions. The identification of a recurrent, inactivating stop-
codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme. The
SDHB mutations in normal PBMCs and leukemic T cells might play a role in cellular pre-adaptation to hypoxia.
Citation: Baysal BE (2007) A Recurrent Stop-Codon Mutation in Succinate Dehydrogenase Subunit B Gene in Normal Peripheral Blood and Childhood
T-Cell Acute Leukemia. PLoS ONE 2(5): e436. doi:10.1371/journal.pone.0000436
INTRODUCTION
Oxygen deprivation (hypoxia) induces adaptive responses in most
organisms and cell types [1] and may contribute to pathogeneses
of common human diseases. Several adaptive responses to hypoxia
are mimicked by hereditary paraganglioma (PGL), a human
genetic disorder characterized by the development of tumors from
the hypoxia-sensitive paraganglionic tissues and caused by germ
line heterozygous inactivating mutations in the nuclear-encoded
SDHB, SDHC or SDHD subunit genes of mitochondrial complex II
(succinate dehydrogenase; SDH; succinate-ubiquinone oxidore-
ductase) [2,3]. PGL mutations or chronic hypoxic exposure
predispose to carotid body (CB) paragangliomas [2]. The PGL
tumors are highly vascular and show global gene expression
profiles of angiogenesis and hypoxic-pathway activation [4].
Lower altitudes are associated with decreased penetrance/
expressivity and increased prevalence of SDHD mutations [5].
Heterozygous inactivation of the mouse Sdhd gene leads to
persistent hypoxic stimulation of the CB paraganglionic cells [6].
These data strongly suggest that constitutive activation of hypoxia-
sensing and signaling pathways, presumably as a consequence of
accumulation of reactive oxygen species [7], succinate [8] and/or
another messenger molecule, underlies PGL pathogenesis. Wheth-
er PGL gene mutations predispose to non-paraganglionic tumors
or system abnormalities is a subject of ongoing investigations [8,9].
In contrast to SDHB and SDHC, mutations in SDHD display
a transmission pattern of maternal genomic imprinting (inactiva-
tion). SDHD mutations cause PGL type 1 (PGL1) after a paternal
but not a maternal transmission. Although no maternal trans-
mission of PGL1 has ever been documented, its molecular basis
remains unclear. Non-paraganglionic tissues display bi-allelic
expression of SDHD, suggesting that imprinting may be confined
to paraganglia [2]. In this report, I demonstrate that the SDHB
subunit gene is targeted by a somatic mutational mechanism in
normal peripheral blood and childhood T-cell acute leukemia.
METHODS
Samples
Peripheral bloods (10–30 mL) were obtained by venipuncture into
EDTA-containing tubes from consenting adults of both sexes and
shipped to author’s laboratory at room temperature. Peripheral
blood mononuclear cells (PBMCs) were isolated by centrifugation
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using BD vacutainer CPTTM tubes (Beckton-Dickinson) and
stored at 2135uC or in liquid nitrogen in freezing media, which
was composed of 90% growth media containing RPMI-1640
(CellGro) and 15% fetal bovine serum (CellGro) and 10% DMSO
(Sigma). A subset of PBMCs was used to immortalize B cells by
Epstein-Barr virus using standard protocols [10]. Diagnostic bone
marrow samples from acute leukemia patients were received in
freezing media from ALL cell bank of Children’s Oncology Group
(COG) and stored at 280uC. Fetal brain and thymus tissues were
collected from 20 week or older fetuses during necropsy and stored
at 280uC. cDNAs synthesized from column-purified normal
PBMC cell-type subsets, including monocytes (CD14+), NK cells
(CD56+, negative selection), B (CD19+) and T lymphocytes
(CD3+), were purchased from AllCells, LLC Inc. through
StemCell Technologies. Each subset was purified from blood
obtained from a different adult subject. The purity and the
viability of the each cell-type subset were on average 94% and
97%, respectively, as confirmed by FACScan analyses. The
leukemia cell lines were purchased from American Type Culture
Collection (ATCC) and grown in the recommended culture
conditions to extract DNA and RNA. The B cell lymphoblastic
leukemia lines included DB, RL and Pfeiffer. The Pfeiffer cell line
contains somatic hypermutations in the rearranged immunoglob-
ulin variable genes [11]. T cell lines included Jurkat, SUP-T1,
TALL-104, MOLT-3, MOLT-4, CEM/C2, which were derived
from child/adolescent acute leukemia, Loucy, which was derived
from adult acute leukemia and HuT 78, HH, which were derived
from cutaneous T cell leukemia. NK-92 is an interleukin-2 (IL-2)
dependent cell line derived from natural killer cell. U-937, THP-1
and AML-193 were derived from acute monocytic leukemia/
lymphoma. All samples were obtained under research protocols
reviewed and approved by the University of Pittsburgh In-
stitutional Review Board (IRB) committee.
Stimulation of PBMCs by phytohemagglutinin (PHA)
PBMCs were freshly isolated from 30 mL peripheral blood drawn
into EDTA tubes by Ficoll-Hypaq density-gradient centrifugation.
One to two million PBMCs were added to three ml of RPMI 1640
media containing 10% fetal bovine serum, 20 U/ml IL-2 (Pepro
Tech) and 2.5 or 5.0 mg/ml of selective T-cell stimulant
phytohemagglutinin PHA-L (Roche Diagnostics) and incubated
at 37uC and 5% CO2 concentration. These recommended PHA
concentrations showed robust T cell stimulation, as assessed by
MTT cell proliferation kit I (Roche Diagnostics), by inducing
activation-induced cell death in the Jurkat cell line. PHA-
stimulated PBMCs were sampled at six hours, days 2, 5 and 8
to extract RNA after determining total cell number and fraction of
dead cells by trypan blue staining in a hemocytometer. The
number of PHA stimulated PBMCs remained unchanged at six
hours and day 2 but increased ,10-fold at days 5 and 8.
Isolation of CD4+ PBMCs
CD4+ cells were isolated from fresh monocyte-depleted PBMCs,
obtained from 30 mL blood, using a positive selection column
following the recommended protocol (EasySepTM, StemCell
Technologies). Monocyte-depleted PBMCs were prepared by
Ficoll-Hypaque density separation using RosetteSepTM monocyte
(CD36) depletion cocktail (StemCell Technologies).
RNA isolation, RT-PCR, PCR amplification, plasmid
cloning, sequencing
Total RNA was isolated by the single-step method of RNA
extraction (RNA-BeeTM, Tel-Test). cDNA was synthesized from
0.1–5 mg of total RNA using Maloney Murine Leukemia Virus
reverse transcriptase (Life Technologies) and oligo(dT) primers
following the recommended protocol. One fifth to one tenth of the
freshly synthesized cDNA was used for nested RT-PCR
amplification. The steady-state fraction of mutant transcripts was
estimated by three semi-independent RT-PCR reactions. For 11
of 179 (6.1%) tested samples, the fraction of mutant transcripts was
estimated by two RT-PCR reactions because of assay failure in
one of the three replicates. The first round of the nested RT-PCR
was performed in three separate reactions using a common
forward primer located in exon 1 (F1A) and a unique reverse
primer located in exons 3 (R13), 5 (R15) or 8 (R10), respectively
(Table S1). The first round PCR products were diluted 1 to 50 in
Tris-EDTA (TE) buffer (pH=8.0) and subjected to second round
PCR employing nested primers F1C and R14, which are located
in exons 1 and 3, respectively. The first-and second round of RT-
PCR employed 30 cycles at 60uC and 61uC annealing tempera-
tures, respectively. By not designing the RT-PCR primers from
exon 2, where the R46X mutation is located, co-amplification of
the gDNA was prevented. Genomic PCR of SDHB exon 2 was
performed using intronic primers FN2A, RN2A and 2R. RT-PCR
amplification of the other SDH subunit genes, SDHA, SDHC and
SDHD were also performed by two rounds of nested PCR using
the primers listed in Table S1. To estimate transcript mutation
rates (Table S2), RT-PCR products were cloned into plasmid
following a commercial protocol (PCR-ScriptTM Amp, Stratagene)
and sequenced by standard automated sequencing after isolating
DNAs from plasmids by alkaline miniprep kits (Qiagene). SDHB
DNA mutation analyses of the leukemic samples were performed
by genomic PCR amplification of each of 8 exons and direct
sequencing as described [12]. In addition to the novel SDHB gene
mutations in TALL-104 and Jurkat, we also identified a previously
reported silent polymorphism, c.24C.T (Ser8Ser) in the SUP-T1
cell line. The DNA mutations were confirmed by alternative
methods including restriction enzyme digestion (for A15T) and
cDNA sequencing (for R217H).
Standard PCR amplifications were performed by Taq poly-
merase (GeneChoice). All PCR amplifications were confirmed by
gel electrophoresis before further analyses. Each PCR reaction
contained 20 pmol of oligonucleotide primers, 1.5 mM of MgCl2
in standard 16 PCR buffer, 0.2 mM of each of the dNTPs and
1 Unit of Taq polymerase. Each amplification plate had water and
TE buffer negative control samples. Both rounds of the RT-PCRs
for the assessment of transcript mutation rates (Table S2) and the
first round of mutation enrichment RT-PCRs (RT-ePCRs)
employed PfuUltra2 enzyme, a high fidelity Taq polymerase
enzyme, following the recommended protocol (Stratagene).
Enrichment PCR for the R46X mutation
To enrich for the mutant DNA molecules, we employed
enrichment RT-PCR (RT-ePCR) and enrichment genomic PCR
(ePCR). RT-ePCR involved overnight-digestion of 10 mL of the
first-round PfuUltra-amplified RT-PCR products by 10 U of TaqI
(New England Biolabs) in a 20 mL reaction volume. The digestion
products were then diluted 1 to 10 in TE buffer and PCR
amplified in the second round. ePCR started with overnight-
digestion of 0.5–1.0 mg of genomic DNA (gDNA) by 10 U of TaqI
(New England Biolabs) in a 20 mL reaction volume. Four mL of the
RE digestion product were then directly used for nested PCR
amplifications in two rounds. The first round ePCR products
amplified by the intronic primers FN2A and 2R were diluted 1 to
50 in TE buffer and subjected to second round PCR amplification
by FN2A and the nested intronic primer RN2A (Table S1).
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Quantification of the R46X mutation by TaqI RE
digestion and capillary gel electrophoresis
The quantification experiments employed the hot-stop PCR
method [13]. We removed the PCR plate at the end of the 29th
cycle of the second round PCR and added 20 pmol of a HEX-
labeled R14 primer (Sigma-Genosys) in a 4 mL 16 PCR buffer.
The 30th (last) cycle of the PCR was completed to produce
fluorescently-labeled homo-duplex extension products. Fifteen mL
of the fluorescently-labeled PCR products, which contained
,200–300 ng of DNA, were directly digested by 10 U of TaqI
RE, 16TaqI RE buffer and 16Bovine Serum Albumin (all from
New England Biolabs) overnight in a 25 mL reaction volume. To
ensure complete digestion, the reaction was re-dosed with another
10 U of TaqI RE in a 5 mL volume and continued for at least
another four hours in the following day. All RE digestion products
were inspected by gel electrophoresis (Fig. S1). The fluorescently-
labeled and TaqI-RE digested PCR products were run in capillary
gel electrophoresis (3100 Avant Genetic Analyzer, ABI Prism,
Applied Biosystems/HITACHI). To quantify the amount of the
mutant fraction, the area under the peak for the mutant
undigested sequence (285 bp) was divided by the sum of the areas
under the peaks for the mutant (undigested) and wild-type
(digested, 126 bp) sequences (See Fig. 1C,D).
Analyses of somatic mutation rates
Nucleotide misincorporation occurs during in vitro synthesis of
cDNA by reverse transcriptase and PCR amplification. The
nucleotide misincorporation rates by Moloney Murine Leukemia
virus (MMLV)/SuperScript III reverse transcriptases, Taq and
PfuUltra DNA polymerases were assumed 6.061025, 861026 and
0.461026 per bp per duplication, respectively [14]. We estimated
the highest effective duplication number of SDHB cDNAs during
the two rounds of nested PCR in PBMCs using control plasmids
containing the wild-type gene. Using serial dilutions, we found that
Figure 1. Analysis of SDHB R46X mRNA mutation. A. The SDHB gene has 843 bp coding nucleotides spread to 8 exons within ,35 kb at
chromosome band 1p36.13. The 59- portion of the gene shows the position of the R46X mutation and the mitochondrial signal peptide cleavage site
(filled circle). B. Sequence chromatograms of RT-PCR products show samples that have high (top), low (middle), or undetectable (bottom) amounts of
mutant R46X sequences. C. Quantification of the mutant fraction involved TaqI RE digestion of fluorescently-labeled RT-PCR products and capillary
gel electrophoresis. The red peaks denote the molecular weight marker. D. The agarose gel electrophoresis shows variable fractions of mutant RT-
PCR products from normal PBMCs detected by TaqI RE digestion, which releases two bands 159 and 126 bp in size from the wild-type sequence (also
see Fig. S1A). E. Fractions of TaqI RE resistant transcripts in the purified PBMC cell types are shown in an agarose gel. The negative image is presented
to enhance the visibility of mutant transcripts.
doi:10.1371/journal.pone.0000436.g001
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after 30 cycles of the first-round PCR, as low as 0.05 fg
(0.05610215 g) of SDHB cDNA plasmids did not produce bands
detectable in the ethidium bromide-stained agarose gel, similar to
the PBMC cDNAs. However, 1 to 50 dilutions of the first-round
PCR products yielded ,400 ng of DNA after the 30 cycle
amplification of the second round nested PCR. (TaqI RE digestion
and gel electrophoreses of the second-round wild-type plasmid
PCR products showed no evidence of mutations within the 4-bp
RE recognition site introduced during amplification by Taq
polymerase.) This enrichment corresponds to ,461011-fold or
,38.5 effective duplications by the nested PCR amplification.
Consequently, the nested RT-PCR by Taq polymerase is expected
to generate errors during cDNA synthesis (6.061025 per bp) and
PCR amplification (38.56861026 per bp), which sums to
,36.861025 per bp (i.e., one error in 2,717 bps). Similarly,
nested RT-PCR by PfuUltra is expected to generate a total error
rate of ,7.5461025 per bp (i.e., one error in 13,263 bp), which
was used to test for excess mutations observed in the cloned-
sequenced RT-PCR products assuming Poisson distribution
(Table S2). Statistical analyses were performed using SISA,
a Simple Interactive Package for Statistical Analysis (http://
home.clara.net/sisa/index.htm).
Control experiments on the R46X mutation
(a) Overall random mutation rate in SDHB transcripts is
not increased in PBMCs We cloned and sequenced SDHB
RT-PCR products obtained from total and monocyte-depleted
CD4+ PBMCs, leukemic cell lines derived from a post-germinal
center B lymphocyte (Pfeifer), a T lymphocyte (Jurkat) and
a natural killer cell (NK-92) (Table S2). The R46X mutation was
observed among the cDNA clones obtained from total and CD4+
PBMCs and the Jurkat cell line. The overall SDHB transcript
mutation rate was increased only in the Jurkat line. The mutation
rates in the control genes SDHA, SDHD and SDHC were not
significantly increased in Jurkat.
(b) The R46X mutation is not introduced during
enzymatic amplification Although absence of the R46X
mutation in the EBV-transformed lymphoblastoid cell lines
strongly suggests that the mutation is not introduced during in
vitro amplification, to further rule out this possibility, we also tested
wild-type SDHB plasmids. On the basis of nucleotide
misincorporation rates, enzymatic amplification of the wild-type
plasmids for 38.5 effective duplications during nested PCR (above)
are expected to generate random mutations in ,0.15% of the
PCR products within the 4 bp-long TaqI RE recognition site.
Accordingly, agarose and capillary gel electrophoreses showed no
evidence of mutations in the TaqI RE recognition site in the PCR
products amplified from 106-fold range of starting wild-type
plasmid DNA amounts (Fig. S1). When wild-type SDHB plasmids
were PCR amplified in the first-round, digested by TaqI RE and
subjected to a second-round PCR (i.e., mutation enrichment PCR,
ePCR), no plasmid template (n = 19) showed the R46X mutation
by direct sequencing. In contrast, all PBMC cDNAs (n= 35) tested
by RT-ePCR showed the R46X mutation by direct sequencing
(Fig. S1B). Finally, the R46X mutation was observed after RT-
PCR amplification either by Taq polymerase or by PfuUltra (Table
S2) and after reverse transcription either by MMLV or by
SuperScript III (Life Technologies) reverse transcriptase enzymes.
(c) Nested PCR amplification does not significantly
distort the starting fractions of mutant cDNAs To test
whether nested PCR amplification of SDHB significantly distorts
the starting fraction of mutant cDNAs, we amplified control
plasmid templates which contained pre-determined fractions of
mutant DNAs and quantified the percentage of mutant molecules
by TaqI RE digestion and capillary gel electrophoresis. Primers
F1C-R10, F1C-R15 and F1C-R13 were used in the first-round of
the nested PCR to generate three replicates for each sample. Each
replicate was diluted 1 to 50 in T.E. buffer and then PCR amplified
by F1C-R14 in the second-round, in the last cycle of which
a fluorescently-labeled R14 primer was added. The confidence
intervals of the expected and the observed percentages of mutant
DNAs overlapped over a 1,000-fold range of starting fractions of the
mutant DNA (Fig. S2) suggesting that nested PCR does not
significantly skew the fraction of mutant DNAs.
(d) The R46X mutation targets the full-length SDHB
coding mRNA sequences Northern analysis indicated that
SDHB is ubiquitously expressed and its transcripts cluster at a single
band at ,1.1 kb size (Fig. S3). RT-PCR, TaqI RE digestion and
gel electrophoresis of PBMC mRNAs showed that R46X occurs in
the full-length SDHB coding mRNA. This is also confirmed by
direct sequencing of 23 clones that have the R46X mutation.
(e) No processed SDHB pseudogene exists in the
gDNA Processed pseudogenes in the gDNA could co-amplify
during RT-PCR and potentially complicate interpretation of
cDNA-based mutation analyses. Sequence of the human genome
does not indicate presence of a pseudogene for SDHB (http://
www.genome.ucsc.edu). Accordingly, PCR amplification of gDNA
by SDHB RT-PCR primers F1A and R13 did not yield any
products in 23 samples (data not shown).
RESULTS
Discovery of SDHB R46X mRNA mutation
While investigating consequences of a PGL-associated SDHB
splice-site mutation IVS1 +1 G.T on transcript splicing in an
affected subject by reverse transcription, nested PCR amplification
(RT-PCR) and direct sequencing we found that a fraction of the
correctly-spliced SDHB complementary DNAs (cDNAs) synthe-
sized from peripheral blood mononuclear cells (PBMCs) contained
a premature termination codon mutation, c.136C.T (R46X)
(Fig. 1A) that was absent in the genomic DNA (gDNA). The R46X
transcript mutation was subsequently identified in several un-
affected subjects in variable fractions by direct sequencing of
PBMC cDNAs (Fig. 1B). The R46X, a pathogenic mutation in
exon 2, has been previously identified in the germ lines of multiple
PGL cases [3] and is predicted to truncate the SDHB protein product
shortly after the mitochondrial signal peptide sequence (Fig. 1A).
Further control experiments, which are explained in detail in
Methods, showed that (a) overall random mutation rate in SDHB
transcripts is not increased in PBMCs (b) the R46X mutation is not
introduced by Taq polymerase; (c) Nested PCR amplification does
not significantly distort the starting fractions of mutant cDNAs; (d)
the R46X mutation targets the full-length SDHB coding mRNA
sequences; (e) no SDHB pseudogene exists in the gDNA.
Quantification of the R46X mutation in PBMCs
To quantify the fraction of SDHB transcripts containing R46X, we
screened a unique TaqI restriction enzyme (RE) recognition site
(TCGA) destroyed by the mutation using fluorescent ‘‘hot-stop’’
RT-PCR, TaqI RE digestion and capillary gel electrophoresis
(Fig. 1C, D). The average fraction of the R46X-containing SDHB
transcripts obtained from PBMCs of normal controls and of
SDHD/C germ line mutation carriers were 5.7% and 5.9% (range
less than 1 to 30%), respectively (Fig. 2). Cloning-sequencing
confirmed that,99% of the TaqI-RE-digestion-resistant RT-PCR
clones from PBMCs were composed of the R46X mutation
(Table 1). When the second round RT-PCR was performed after
removing the wild-type sequences from the first round products by
SDHB Mutation in Normal Blood
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TaqI RE digestion (i.e., enrichment RT-PCR; RT-ePCR), all
tested PBMCs showed the R46X mutation by direct sequencing
(see Methods). Thus, the average inactivation rate of SDHB
mRNAs in PBMCs is ,10,000-fold higher than would be
expected from all background in vivo somatic inactivating DNA
mutations as measured in the HGPRT gene in normal adult
peripheral blood T lymphocytes [15]. The levels of the mutated
SDHB transcripts in PBMCs are comparable to the C-to-U-edited
neurofibromatosis 1 (NF1) mRNAs that occur in substantial levels
(.3%) in certain NF1-related tumors, but not in normal tissues,
and are thought to be catalyzed by the apolipoprotein B mRNA-
editing enzyme APOBEC-1 [16].
Analyses of the R46X mutation in PBMC cell-type
subsets
Because PBMCs are primarily composed of lymphocytes and
monocytes, we analyzed cDNAs obtained from purified peripheral
blood monocytes, natural killer (NK) cells, T and B lymphocytes.
The fraction of mutant transcripts was higher in monocytes and
NK cells than in T and B lymphocytes (Figure 1E). Cloning-
sequencing of TaqI-RE-digestion-resistant band from the mono-
cytes confirmed the R46X mutation in 32 of 37 (86%) clones
(Table 1). Mutation enrichment RT-PCR (RT-ePCR) analyses
confirmed the presence of R46X mutation in each of the PBMC
cell-type subset (data not shown).
Analyses of the R46X mutation in leukemic cell lines
To test presence of the R46X transcript mutation in leukemic cell
lines derived from PBMCs, we amplified SDHB cDNAs mutated at
the TaqI RE site by RT-ePCR. Cloning-sequencing of TaqI-RE-
digestion-resistant products showed the R46X mutation in 27 of
54 (50%) clones in the T cell leukemia cell lines but only in 2 of 26
(7.7%) clones in NK-92, which is derived from an NK cell, in 2 of
23 (8.7%) in Pfeiffer, which is derived from a post-germinal center
B lymphocyte, and in 9 of 56 (16.1%) of THP-1, which is derived
from a monocyte (Table 1). The number of clones with the R46X
mutation was statistically significantly overrepresented only in the
T-ALL cell lines relative to the random somatic mutation profiles
[15] (Table 1). Furthermore, the overall transcription mutation
rate in SDHB but not SDHA, SDHC and SDHD was increased in
the Jurkat T cell line (Table S2).
Analyses of the R46X mutation in primary leukemic
and various other samples
Next, we compared the TaqI-resistant mutant transcript fractions
in a total of 175 samples including EBV-transformed lympho-
blastoid cell lines, which are derived from peripheral blood B cells,
various commercial leukemic cell lines (see Methods), diagnostic
bone marrow samples from childhood T- and B-ALL, PBMCs
treated by T cell-stimulant phytohemagglutinin (PHA), fetal
thymus and brain tissues and non-mutant wild-type plasmid
control DNAs. Substantial levels (.3%) of TaqI-RE-digestion-
resistant mutant transcripts were observed in five of 20 diagnostic
primary T-ALL samples (Fig. 2). Cloning-sequencing of the TaqI-
digestion resistant bands from T-ALL primary samples uncovered
the R46X mutation in 27 of 43 (62%) clones (Table 1). Because
primary diagnostic leukemic bone marrow samples are signifi-
cantly enriched for the lineage-specific lymphocytes, these results
further suggest that the mutational mechanism targeting the SDHB
mRNA remains functional in leukemic T cells.
Figure 2. The steady-state fraction of mutant SDHB cDNAs resistant to TaqI RE digestion. Each circle represents a sample from a different subject
(total indicated by n) except for those in the PHA stimulated PBMCs which were obtained from two normal donors, stimulated by 2.5 mg/ml and
5.0 mg/ml concentrations of PHA and tested at days 2, 5 and 8 for a total of 12 samples. The value corresponding to each circle was derived from
three RT-PCR reactions. Two outlier PBMC values were shown at the top with their mutant transcript fractions in parentheses. Boxes and the vertical
lines denote the means and their 95% confidence intervals of samples sets. ‘‘PBMC mutation carrier’’ group contains 5 SDHC and 24 SDHD mutation
carriers. The leukemic cell lines were derived from B cells (n = 3), T cells (n = 9), NK cells (n = 1) and monocytes (n = 2).
doi:10.1371/journal.pone.0000436.g002
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Analyses of the R46X mutation in genomic DNA
(gDNA)
To test whether the R46X mutation also occurs in the gDNA of
PBMCs, we initially PCR-amplified SDHB exon 2 from 22
samples and digested it with TaqI RE. Gel electrophoresis of the
RE digestion products showed no evidence of the mutation
(Fig. 3A), including in the sample that showed the highest fraction
of the mutant cDNA (30.2% in Fig. 2). To test whether the R46X
mutation exists in the gDNA at very low levels, we employed
enrichment PCR (ePCR), which involved removal of the non-
mutant wild-type gDNA by TaqI RE digestion before nested PCR
amplification. Analyses of the ePCR products by TaqI RE
digestion and gel electrophoresis showed variable fractions of
mutant molecules in PBMC gDNAs (Fig. 3B). Direct sequencing of
ePCR products showed the R46X mutation in 3 of 24 samples
(Fig. 3D). Cloning-sequencing of the TaqI RE digestion-resistant
ePCR products from these three samples showed the R46X
mutation in 27 of 30 clones (90%) confirming that the ePCR
method statistically significantly enriched for the R46X mutation
(Table 1). These findings indicate that the R46X mutation
identified in SDHB cDNA also occurs in the gDNA at a much
lower frequency.
To test whether genomic R46X mutation also occurs in the
leukemic cell lines, we employed ePCR on the gDNAs of 11
leukemic cell lines including four originating from T cells (Jurkat,
CEM/C2, Loucy, MOLT-4), three from B cells (Pfeiffer, DB and
RL), three from monocytes (AML-93, U-937, THP-1) and one
from NK cells (NK-92). Analyses of the ePCR products by TaqI
RE digestion and gel electrophoresis uncovered the presence of
mutant bands in the CD4+ T-ALL cell lines MOLT-4 and Jurkat
in three replicate experiments (Fig. 3C). Cloning-sequencing of the
TaqI RE digestion-resistant bands from MOLT-4 and Jurkat
uncovered R46X in 43 of 54 clones (,80%) (Table 1),
demonstrating a statistically significant enrichment of the muta-
tion. These results further suggest that the R46X mutation occurs
in leukemic T lymphocytes.
SDHB gene sequencing in PBMC-derived leukemic
cell lines
We sequenced all eight SDHB gene exons in 16 leukemic cell line
DNAs, including those derived from T, B, NK cells and
monocytes, and found novel expressed DNA sequence alterations
in two of six childhood T-ALL cell lines. The Arg217His mutation
in TALL-104 (Fig. 3E) targets an amino acid residue conserved in
497 of 500 SDHB sequence entries from diverse organisms in
GenBank and its distinct germ line missense mutation, Arg217Cys,
is previously linked to PGL susceptibility [3]. The Ala15Thr
mutation in Jurkat (Fig. 3F) decreases hydrophocity of the
mitochondrial signal peptide by converting a non-polar to a polar
residue. The mutated alanine is conserved in 20 of 23 multicellular
eukaryotic organisms which have the orthologous signal peptide
sequences including fly, chicken and mammals (Fig. S4). These
two missense variants were not present in the SDHB orthologous
amino acid positions in other organisms in GenBank, in over 200
human chromosomes that we previously sequenced, and have not
been reported as population variants in extensive mutation surveys
of PGL [3]. No SDHB gDNA mutations were detected in 20 T-
ALL primary diagnostic samples.
DISCUSSION
The current study describes identification of substantial levels of
SDHB transcripts carrying a recurrent R46X mutation in normal
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PBMCs. Analyses of the purified PBMC cell-types suggest
monocytes and NK cells as the major sources of the mutant
transcripts, although T and B lymphocytes also contribute at lower
levels. In contrast, analyses of leukemic cell lines and bone marrow
samples uncover the R46X transcripts only in T-ALL. The R46X-
mRNAs constitute on average 5.8% of all SDHB transcripts in
PBMCs, strongly suggesting that a cytidine deaminase enzyme(s)
catalyzes this somatic mutation.
Programmed somatic mutations targeting cytidine residues in
protein-encoding mammalian nuclear genes were previously
observed in two normal cell types: the post-germinal center B
lymphocytes during diversification of immunoglobulins by the
process of somatic hypermutation [17] and in intestinal cells to
generate a shorter protein isoform (ApoB48) of apolipoprotein B
by RNA editing [18]. The mutations in the immunoglobulin and
apolipoprotein B loci confer new properties to the targeted gene
products (i.e., gain-of-function). The R46X mutation in SDHB is
unusual because it predicts loss-of-function, it targets a classical
tumor-suppressor gene, and it occurs in PBMCs.
The results described here prompt important questions on
mechanism and significance of SDHB mRNA mutations identified
in normal PBMCs and leukemic T cells. The current results show
that the R46X mutation is present at much higher proportions in
mRNA than in DNA. This finding could be explained by two
models. First, the putative mutator enzyme may target both DNA
and mRNA, the latter with a higher efficiency. Alternatively, the
mutator enzyme may target only DNA, which is then repaired
after the transcription. The presence of sequence heterogeneity
and A/T mutations in the TaqI RE recognition site (e.g., in the T-
ALL bone marrow samples in Table 1) supports the second model
because such sequence variants suggest operation of an error-
prone repair mechanism in the leukemic T cells. The error-prone
DNA repair of uracil residues is thought to be responsible for the
generation of A/T mutations during antibody diversification in B
cells by the activation-induced cytosine deaminase (AID) enzyme
[19].
Another important question concerns the causes of variation in
the fraction of R46X-mRNAs obtained from total PBMCs.
Heritable or acquired conditions such as infections, medications,
exercise and diurnal rhythm might influence the relative
abundance of PBMC cell-type subsets and, consequently, the
fraction of the R46X-mRNAs. Alternatively, technical factors such
as the length of time span and the storage conditions between the
blood draw to the PBMC isolation procedure might affect the cell
viability. Furthermore, if the R46X-mRNAs are variably targeted
by nonsense-mediated decay, an intra-cellular surveillance mech-
anism that removes the transcripts containing premature termi-
nation codons [20], the steady-state fraction of mutant SDHB
mRNAs would underestimate the true fraction of mutated
transcripts in certain samples or PBMC cell-type subsets. Although
each of these factors might influence the proportion of mutated
SDHB mRNAs in a given sample, the present results indicate that
the R46X mRNA mutation occurs in every tested PBMC sample
at significantly higher levels compared to the control lympho-
blastoid cell lines or wild-type plasmid templates. The identifica-
tion of distinct heterozygous missense SDHB gene mutations in
two T-ALL cell lines further suggests that the R46X mutation
might play a functional role in the biology of PBMCs and leukemic
T cells.
The genetic regulation of SDH subunits appears to be emerging
as a common motif in several normal cell types. First, the
transmission pattern of PGL1 tumors suggests that the SDHD
subunit gene is suppressed on the maternal allele by genomic
imprinting in the paraganglionic tissues [2]. The SDHD mutations
or chronic hypoxic exposure cause paragangliomas in the carotid
body (CB). Notably, the CB is the major oxygen sensor organ in
mammals and stimulates the cardiopulmonary system within
seconds of exposure to hypoxia. Second, the SDHA gene, which
encodes the major catalytical subunit (flavoprotein) of SDH,
carries a strong signature of balancing selection in the African
chromosomes [21]. Distinct SDHA alleles, including two missense
variants at amino acid residues conserved in mammals, have been
Figure 3. SDHB mutations in genomic DNAs (gDNAs). A. TaqI RE digestion of PCR-amplified exon 2 shows no evidence of undigested mutant DNAs
at 260 bp size (pointed by an arrow head). TaqI RE digestion products of the wild-type DNA co-migrate at sizes of 128 and 132 bps (denoted by
a star). B. Gel electrophoresis of TaqI RE-digested (mutation) enrichment PCR (ePCR) products shows variable amounts of mutant gDNAs at 233 bp
size (pointed by an arrow head), which are confirmed to be primarily composed of c.136C.T by sequencing (Table 1). TaqI digestion of wild-type
ePCR products gives two bands at sizes, 101 and 132 bp (shown by a star). C. ePCR analyses of leukemic cell lines demonstrate the presence of
mutant gDNA in the MOLT-4 cell line (pointed by an arrow head) but not in other leukemic cell lines in this experiment. D. Direct sequence analysis of
a gDNA ePCR product shows selective enrichment of the R46X mutation. E, F. Sequence chromatograms of the heterozygous DNA mutations
detected in two T-ALL cell lines are shown.
doi:10.1371/journal.pone.0000436.g003
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maintained at intermediate frequencies for long evolutionary
periods. Thus, certain SDHA allelic variants that have slight
functional deficits might confer protection against pathogens or
toxins that are prevalent in Africa. Finally, the present results
demonstrate a recurrent SDHB mutation in normal PBMCs and
leukemic T cells. Although many gaps exist in our knowledge on
the mechanisms of imprinting on SDHD, balancing selection on
SDHA and transcript mutations in SDHB, including their impact
on SDH enzyme activity, the extant data on PGL suggest that
these regulatory mechanisms might downregulate SDH function
and facilitate early detection of and pre-adaptation to hypoxia
(Figure 4).
It is well-known that blood monocytes differentiate into
macrophages in solid tissues and accumulate in large numbers in
chronically hypoxic avascular and necrotic areas in infected and
neoplastic organs [22,23]. The SDHB somatic transcript mutations
might enable earlier activation of hypoxia inducible pathways and
increase survival of monocytes and natural killer cells in these
hypoxic areas. A similar survival advantage might be conferred to
leukemic T cells as they shuttle between the well-oxygenated
peripheral blood and the more hypoxic immune-system organs. In
conclusion, the present results suggest that the SDHB gene is
targeted by a somatic mutational mechanism that likely involves
the activity of a cytidine deaminase enzyme expressed in PBMCs
and leukemic T cells. If the somatic SDHBmutations are proven to
play a role in oxygen homeostasis in PBMCs and leukemic T cells,
targeting of the SDH complex might provide new therapeutic tools
against infections, leukemia and cancer.
SUPPORTING INFORMATION
Figure S1 Detecting the R46X mutation in agarose gel
electrophoresis. Each test set contains 16 different samples. The
second-round RT-PCR products remaining undigested after the
TaqI RE digestion at 285 bp (examples shown by arrows) indicate
the presence of mutations within the 4-bp RE recognition. Highest
levels of mutations were observed in the PBMC and T-ALL
samples (also see Figure 2). Plasmid controls demonstrate outcome
of the experiment when plasmids (,4.0 kb) containing the wild-
type SDHB cDNA were used for nested PCR amplification at
various starting amounts shown by numbers 1 to 4. Total plasmid
input amounts: 1 = 28 ng, 2= 0.28 ng, 3 = 2.8 pg, 4 = 28 fg. B.
Enrichment of R46X by enrichment RT-PCR (RT-ePCR) in
PBMCs. RT-ePCR involved removal of the wild-type sequences
by TaqI digestion before the second-round PCR. Direct
sequencing of second-round RT-ePCR products confirmed
presence of the R46X mutation in all tested PBMCs (n= 35) but
in none of the control wild-type plasmid templates (n = 19) nor in
the lymhoblastoid cell lines (n = 14).
Found at: doi:10.1371/journal.pone.0000436.s001 (0.18 MB TIF)
Figure S2 Fraction of mutant cDNAs before and after PCR
amplification. Mutant and wild-type plasmid DNAs that have full-
length SDHB cDNAs were mixed in variable amounts to generate
control template sets (denoted by letters A–I) for nested PCR.
(Image for set E was re-positioned at the end of other sets from the
lower half of the gel.) Each template set was composed of two
samples (shown by numbers 1 and 2) that have the same fraction of
mutant DNAs but different starting amounts of total plasmid [,20
and 5 fg (10–15 g), respectively]. The top of the figure shows Taq
I RE digestion results of the second round PCR products that were
amplified by F1C-R10, F1C-R15 (shown under the gel pictures) in
the first-round and F1C-R14 in the second round. Graph at the
bottom shows, on a logarithmic scale, the average percentages
(denoted in parentheses) of the expected (starting) and observed
(measured after nested PCR) ratios of mutant/wild type plasmids
in the test sets. The confidence intervals (delimited by plus signs)
for the expected percentages were derived from the most extreme
values of plasmid DNA concentrations that were obtained from
multiple (n = 7) spectrophotometric measurements. For the
observed percentages, 95% confidence intervals were derived
from quantification of the six replicates in each set. The lower
boundaries of the observed confidence intervals for sets G, H were
zero. Set I, which is not shown in the graph, has 0.02% expected
and 0% observed mutant DNAs, respectively.
Found at: doi:10.1371/journal.pone.0000436.s002 (0.09 MB TIF)
Figure S3 Northern analysis of SDHB mRNA. SDHB is
ubiquitously expressed and its transcripts cluster at a single band
of ,1.1 kb size. Multiple Tissue Northern (MTNTM, CLON-
TECH) Blot contained ,2 microgram of mRNA in each lane.
The hybridization probe was generated by RT-PCR amplification
of the full-length SDHB gene by primers F1A-R9 (Table S1) and
Figure 4. SDH genetic downregulation as a mechanism for early detection of hypoxia. Data from PGL research suggest that SDH normally
inactivates a messenger(s) critical for downstream hypoxia-signaling. Consequently, heterozygous SDH germ line mutations over-activate the hypoxia
signaling pathways in PGL. Loss of the wild-type allele by loss-of-heterozygosity (LOH) leads to constitutive hypoxic signaling and tumorigenesis in
PGL. Transcript mutations, genomic imprinting, balancing selection or germ line mutations are postulated to reduce SDH activity and change the
hypoxia-detection threshold from a lower oxygen concentration (a) to higher oxygen concentrations (b, c), thus leading to earlier detection of
impending hypoxia.
doi:10.1371/journal.pone.0000436.g004
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labeled by 32P following the random priming method using
a commercial protocol (High Prime, Roche).
Found at: doi:10.1371/journal.pone.0000436.s003 (0.05 MB TIF)
Figure S4 The Ala15Thr mutation in Jurkat cell line. Multiple
sequence alignment (Clustal W 1.83) of N-terminal sequences of
SDHB gene products demonstrates that human Ala15 is conserved
(shown by red fonts) in most organisms which are denoted by their
genus names. All sequences detected by the default parameters of
BLAST analyses (http://www.ncbi.nlm.nih.gov/BLAST) are
shown.
Found at: doi:10.1371/journal.pone.0000436.s004 (0.05 MB TIF)
Table S1 Oligonucleotide PCR primers used to amplify SDH
subunit genes by nested PCR. * Primers used in both rounds of the
nested PCR.
Found at: doi:10.1371/journal.pone.0000436.s005 (0.04 MB
DOC)
Table S2 Transcript mutations in SDH subunit genes. *1
misincorporation per 13,263 bp on the basis of RT-PCR
amplification by PfuUltra. Ns =not significant
Found at: doi:10.1371/journal.pone.0000436.s006 (0.04 MB
DOC)
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